SavedAdd your journal

Journals / European Journal of Therapeutics / 2018 / Cilt: 24 - Sayı: 1

Molecular Genetic Testing and Liquid Biopsy in Lung Cancer: Present and Future

Seçil EROĞLU
Sibel OĞUZKAN BALCI
Pages
14–18
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This reviewwill summarize clinically significant key genetic biomarkers and focus on liquid biopsy which means analyzing of noninvasivebiomarkers such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), circulating miRNAs and exosomes.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The genetic landscape of lung cancer has been expanded over decades with advancements in molecular genetic technologies.Despite improvements, the survival rate of lung cancer is still low.
📊
Key Findings & Data:When diagnosed at an early stage, resection of tumor or lobectomyis possible, survival rate increases accordingly.
💡
Conclusion & Impact:This reviewwill summarize clinically significant key genetic biomarkers and focus on liquid biopsy which means analyzing of noninvasivebiomarkers such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), circulating miRNAs and exosomes.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

The genetic landscape of lung cancer has been expanded over decades with advancements in molecular genetic technologies.Despite improvements, the survival rate of lung cancer is still low. When diagnosed at an early stage, resection of tumor or lobectomyis possible, survival rate increases accordingly. Therefore it is crucial to identify diagnostic or predictive biomarkers anddevelop new technologies which can efficiently analyze these biomarkers. Since lung tumor tissue is difficult for sampling andrequires invasive procedures, identification of non-invasive blood-based tumor biomarkers has become attractive recently. This reviewwill summarize clinically significant key genetic biomarkers and focus on liquid biopsy which means analyzing of noninvasivebiomarkers such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), circulating miRNAs and exosomes.

🔖

Cite This Article

EROĞLU, S., BALCI, S. O. (2022). Molecular Genetic Testing and Liquid Biopsy in Lung Cancer: Present and Future. European Journal of Therapeutics, Cilt: 24 - Sayı: 1, 14–18. https://ajindex.com/articles/512315

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Awad MM, Katayama R, McTigue M, Liu W, Deng, YL, Brooun A., et al. Acquired resistance to crizotinib from a mutation in CD74-ROS1. N Eng J Med 2013
  2. [CrossRef] Bayarri-Lara C, Ortega FG, Cueto Ladrón de Guevara A, Puche JL, Zafra, JR, de Miguel-Pérez D, et al. Circulating tumor cells identify early recurrence in patients with non-small cell lung cancer undergoing radical resection. PloS One, 2016
  3. 0148659. [CrossRef] Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 2012
  4. [CrossRef] Bettegowda C, Sausen M, Leary R J, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early-and late-stage human malignancies. Sci Transl Med 2014
  5. 224ra24. [CrossRef] Campbell JD, Alexandrov A, Kim J, Wala J, Berger AH, Pedamallu CS, et al. Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nat Genet 2016
  6. [CrossRef] Catarino R, Coelho A, Araújo A, Gomes M, Nogueira A, Lopes C, et al. Circulating DNA: diagnostic tool and predictive marker for overall survival of NSCLC patients. PloS One 2012
  7. e38559. [CrossRef] Chow A, Zhou W, Liu L, Fong MY, Champer J, Van Haute D, et al. Macrophage immunomodulation by breast cancer-derived exosomes requires Toll-like receptor 2-mediated activation of NF-κB. Sci Rep 2014
  8. [CrossRef] De Greve J, Teugels E, Geers C, Decoster L, Galdermans D, De Mey J, et al. Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. Lung Cancer 2012
  9. [CrossRef] Dejima H, Iinuma H, Kanaoka R, Matsutani N, Kawamura M. Exosomal microRNA in plasma as a non invasive biomarker for the recurrence of non small cell lung cancer. Oncology let 2017
  10. [CrossRef] Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med 2008
  11. [CrossRef] Douillard J, Ostoros G, Cobo M, Ciuleanu T, Cole R, McWalter G, et al. Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status. J Thorac Oncol 2014
  12. [CrossRef] Drilon A, Rekhtman N, Arcila M, Wang L, Ni A, Albano M, et al. Cabozantinib in patients with advanced RET-rearranged non-smallcell lung cancer: an open-label, single-centre, phase 2, single-arm trial. Lancet